Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01828021
Title Phase 2 Study of the Monoclonal Antibody MGAH22(Margetuximab)in Patients With Relapsed or Refractory Advanced Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors MacroGenics
Age Groups: adult
Covered Countries USA

No variant requirements are available.